Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 41,124 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The shares were sold at an average price of $206.16, for a total value of $185,956.32.
• On Monday, April 27th, Steven Leonard Chapman sold 5,838 shares of Natera stock. The shares were sold at an average price of $204.14, for a total value of $1,191,769.32.
• On Tuesday, March 10th, Steven Leonard Chapman sold 5,623 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $1,147,822.99.

Natera Price Performance

NASDAQ:NTRA traded down $6.79 during midday trading on Friday, reaching $215.31. 848,951 shares of the company traded hands, compared to its average volume of 1,640,936. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The firm has a market capitalization of $30.83 billion, a price-to-earnings ratio of -132.09 and a beta of 1.56. The company has a fifty day moving average price of $204.19 and a 200 day moving average price of $216.06.

Institutional Investors Weigh In On Natera

Hedge funds have recently bought and sold shares of the company. Reflection Asset Management bought a new stake in Natera during the fourth quarter valued at about $29,000. Palladiem LLC bought a new position in Natera during the fourth quarter worth about $31,000. Horizon Investments LLC bought a new position in Natera during the third quarter worth about $32,000. International Assets Investment Management LLC lifted its stake in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares during the period. Finally, Bank of Jackson Hole Trust raised its stake in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NTRA. Morgan Stanley decreased their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. William Blair initiated coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating for the company. Evercore reissued an “outperform” rating and set a $270.00 target price on shares of Natera in a research note on Friday, May 8th. Piper Sandler reissued an “overweight” rating and set a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $256.12.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.